[Evidence-based evaluation of study results of symptomatic glucosamine therapy].
Meta-analyses can contribute to the field of evidence based medicine. In the systematic analyses so far published, the symptomatic efficacy of glucosamine was described to be moderate to large. The results of the individual clinical studies however do not support these findings unanimously. In the past couple of years, some new studies of high quality standard were published. This publication gives an overview and an evaluation of the current available studies for the symptomatic treatment of patients with gonarthrosis with glucosamine. It also compares the results of the individual studies with those of recent meta-analyses.
Reiter
S
S
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Kurt-Georg-Kiesinger-Allee 3, 53175 Bonn, Germany.
D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D018771:Arthralgia / Q000453:epidemiology* / Q000517:prevention & control*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D015897:Comorbidity; D019317:Evidence-Based Medicine; D005944:Glucosamine / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D010003:Osteoarthritis / Q000188:drug therapy* / Q000453:epidemiology*; D010166:Palliative Care / Q000379:methods / Q000706:statistics & numerical data; D011379:Prognosis; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D016896:Treatment Outcome
D018712:Analgesics, Non-Narcotic; D018501:Antirheumatic Agents; D005944:Glucosamine